FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Privates continue to lag public clouds

Free Newsletter

FierceBiotech IT updates senior biotech, pharma, and IT leaders on how IT advances are shaping clinical trials and clinical research. Get your weekly briefing on clinical trial design and management systems, adaptive trials, eClinical trials, and more. Sign up today!



Tools

As Amazon continues to distance itself from the public-cloud computing provider pack, private clouds remain a not-ready-for-prime-time alternative. So says Chris Dagdigian of high-performance computing consultancy BioTeam.

Dagdigian spoke at the recent Bio-IT World Europe conference. In a published interview, he says that viable private cloud computing--for life-sciences applications, at least--remain one or more years in the future. The reason: inadequate flexibility of internal network architecture for meeting business and scientific needs.

A major appeal of private networks over clouds, of course, is their tighter data security--a storage issue that instantly attracts C-level attention, in contrast to the science-driven computing requirements that lead researchers to the cloud in the first place. But public cloud providers and users alike contend that security concerns are overblown. Now they just have to get the corporate suite to listen. Or are the corporados right?

- read the Dagdigian interview
- see our Fierce cloud services report

Related Articles:
J&J culls apps for move to cloud
The cloud that broke the CIOs' backs


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotechIT Email Newsletter:

More stories about Data Security   Private Networks   biotech cloud computing